These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16056257)

  • 21. The Ag85B protein of Mycobacterium tuberculosis may turn a protective immune response induced by Ag85B-DNA vaccine into a potent but non-protective Th1 immune response in mice.
    Palma C; Iona E; Giannoni F; Pardini M; Brunori L; Orefici G; Fattorini L; Cassone A
    Cell Microbiol; 2007 Jun; 9(6):1455-65. PubMed ID: 17250590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
    Hervas-Stubbs S; Majlessi L; Simsova M; Morova J; Rojas MJ; Nouzé C; Brodin P; Sebo P; Leclerc C
    Infect Immun; 2006 Jun; 74(6):3396-407. PubMed ID: 16714570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuberculosis vaccines--rethinking the current paradigm.
    Andersen P; Woodworth JS
    Trends Immunol; 2014 Aug; 35(8):387-95. PubMed ID: 24875637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational design of vaccines against tuberculosis directed by basic immunology.
    Reece ST; Kaufmann SH
    Int J Med Microbiol; 2008 Jan; 298(1-2):143-50. PubMed ID: 17702652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
    Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mouse and guinea pig models for testing new tuberculosis vaccines.
    Orme IM
    Tuberculosis (Edinb); 2005; 85(1-2):13-7. PubMed ID: 15687022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a new recombinant BCG which contains mycobacterial antigen ag85B-mpt64(190-198)-mtb8.4 in C57/BL6 mice.
    Qie YQ; Wang JL; Zhu BD; Xu Y; Wang QZ; Chen JZ; Wang HH
    Scand J Immunol; 2008 Feb; 67(2):133-9. PubMed ID: 18201368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement C5a anaphylatoxin is an innate determinant of dendritic cell-induced Th1 immunity to Mycobacterium bovis BCG infection in mice.
    Moulton RA; Mashruwala MA; Smith AK; Lindsey DR; Wetsel RA; Haviland DL; Hunter RL; Jagannath C
    J Leukoc Biol; 2007 Oct; 82(4):956-67. PubMed ID: 17675563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The success and failure of BCG - implications for a novel tuberculosis vaccine.
    Andersen P; Doherty TM
    Nat Rev Microbiol; 2005 Aug; 3(8):656-62. PubMed ID: 16012514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New vaccines against tuberculosis.
    Mark Doherty T
    Trop Med Int Health; 2004 Jul; 9(7):818-26. PubMed ID: 15228493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model.
    Fan X; Gao Q; Fu R
    Microbiol Res; 2009; 164(4):374-82. PubMed ID: 17764918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.
    Dietrich J; Doherty TM
    APMIS; 2009 May; 117(5-6):440-57. PubMed ID: 19400867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Strategies for the development of new tuberculosis vaccines].
    Fattorini L
    Minerva Med; 2007 Apr; 98(2):109-19. PubMed ID: 17519853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tuberculosis vaccine.
    Sarhan MA
    Saudi Med J; 2010 Jan; 31(1):9-13. PubMed ID: 20062891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological responses and protective immunity against tuberculosis conferred by vaccination of Balb/C mice with the attenuated Mycobacterium tuberculosis (phoP) SO2 strain.
    Aguilar D; Infante E; Martin C; Gormley E; Gicquel B; Hernandez Pando R
    Clin Exp Immunol; 2007 Feb; 147(2):330-8. PubMed ID: 17223975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvants in tuberculosis vaccine development.
    Moreno-Mendieta SA; Rocha-Zavaleta L; Rodriguez-Sanoja R
    FEMS Immunol Med Microbiol; 2010 Feb; 58(1):75-84. PubMed ID: 20002177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-gamma Low producer genotype +874 overrepresented in Bacillus Calmette-Guerin nonresponding children.
    Anuradha B; Rakh SS; Ishaq M; Murthy KJ; Valluri VL
    Pediatr Infect Dis J; 2008 Apr; 27(4):325-9. PubMed ID: 18379373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression and immunogenicity of recombinant Mycobacterium bovis Bacillus Calmette-Guérin strains secreting the antigen ESAT-6 from Mycobacterium tuberculosis in mice.
    Wang LM; Shi CH; Fan XL; Xue Y; Bai YL; Xu ZK
    Chin Med J (Engl); 2007 Jul; 120(14):1220-5. PubMed ID: 17697571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice.
    Xu Y; Zhu B; Wang Q; Chen J; Qie Y; Wang J; Wang H; Wang B; Wang H
    FEMS Immunol Med Microbiol; 2007 Dec; 51(3):480-7. PubMed ID: 17919299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response and protection by DNA vaccines expressing antigen 85B of Mycobacterium tuberculosis.
    Pardini M; Giannoni F; Palma C; Iona E; Cafaro A; Brunori L; Rinaldi M; Fazio VM; Laguardia ME; Carbonella DC; Magnani M; Ensoli B; Fattorini L; Cassone A
    FEMS Microbiol Lett; 2006 Sep; 262(2):210-5. PubMed ID: 16923077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.